Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Craig-Hallum Upgrades Nautilus to Buy, Announces $9 Price Target

Craig-Hallum analyst Steven Dyer upgrades Nautilus (NYSE:NLS) from Hold to Buy and announces $9 price target.

byBenzinga Newsdesk

February 10, 2022

1 minute read

Craig-Hallum analyst Steven Dyer upgrades Nautilus (NYSE:NLS) from Hold to Buy and announces $9 price target.

Keybanc Maintains Overweight on Smartsheet, Raises Price Target to $48

By Benzinga Newsdesk

Today, 3:09 AM

Keybanc analyst Jason Celino maintains Smartsheet (NYSE:SMAR) with a Overweight and raises the price target from $46 to $48.

SMAR

Analyst Ratings

Expert Ratings For Pfizer

By Benzinga Insights

Today, 3:09 AM

Analysts have provided the following ratings for Pfizer (NYSE:PFE) within the last quarter:

PFE

Reported Early Wednesday, Alvotech 9Months EPS $(1.00) Up From $(3.48) YoY, Sales $59.20M Up From $2.00M YoY

By Benzinga Newsdesk

Today, 3:09 AM

Revenue for first nine months of 2022 increased to $59.2 million, compared to $2.0 million for the same period in 2021

ALVO

Cabaletta Bio Q3 EPS $(0.45) Beats $(0.50) Estimate

By Benzinga Newsdesk

Today, 3:09 AM

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.50) by 10 percent. This is a 25 percent decrease over losses of $(0.36) per share from the same

CABA

Craig-Hallum Upgrades Nautilus to Buy, Announces $9 Price Target

Related Posts

Keybanc Maintains Overweight on Smartsheet, Raises Price Target to $48

Expert Ratings For Pfizer

Reported Early Wednesday, Alvotech 9Months EPS $(1.00) Up From $(3.48) YoY, Sales $59.20M Up From $2.00M YoY

Cabaletta Bio Q3 EPS $(0.45) Beats $(0.50) Estimate